Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.

J Am Heart Assoc · 2016 · PMC4937278 · PMID 27247336

Europe PMC DOI

hedged sentences

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

a nonsignificant trendP =0.18not close (p > 0.1)

There was a nonsignificant trend toward reduced overall 12‐month MACE (17.1% versus 10.5%, P =0.18) driven mainly by a reduced incidence of heart failure ( P =0.04).

also in 3,449 other papers

a strong trendno p-value reported

Brener et al 7 demonstrated a strong trend toward reduced total infarct size measured on CMR at 30 days with prasugrel compared with clopidogrel in acute anterior STEMI treated with PPCI (16.4% versus 17.6% left ventricular mass, P =0.06).

also in 3,343 other papers

a weak trendno p-value reported

18 The higher infarct size and MVO incidence occurred despite a weak trend toward greater degree of IRA collateralization, which can attenuate infarct size and MVO, 19 , 20 in the patients receiving clopidogrel.

also in 834 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.